| MeSH term | MeSH ID | Detail |
|---|---|---|
| Nocturia | D053158 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
| Shin BH et al. | Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. | 2014 | Transplantation | pmid:24342979 |
| Yoon SH et al. | CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | 2013 | Transplantation | pmid:23364483 |
| Cvetkovic M et al. | The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. | 1994 | Transplantation | pmid:7513912 |
| Benito N et al. | Alternariosis after liver transplantation. | 2001 | Transplantation | pmid:11740399 |
| Hodge G et al. | Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. | 2010 | Transplantation | pmid:20559033 |
| Yun J et al. | Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. | 2010 | Transplantation | pmid:20559109 |
| Schäffer MR et al. | Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. | 1998 | Transplantation | pmid:9539093 |
| Anderson PO | Tacrolimus and breastfeeding. | 1998 | Transplantation | pmid:9539100 |
| Berenguer M et al. | Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. | 2010 | Transplantation | pmid:21068701 |
| Weir MR et al. | Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. | 2017 | Transplantation | pmid:26950714 |
| Manez R et al. | Rejection and hepatitis in liver transplants. | 1994 | Transplantation | pmid:7517080 |
| Cao W et al. | Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. | 1995 | Transplantation | pmid:7532879 |
| Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
| Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
| Migita K et al. | FK506 potentiates steroid-induced T-cell apoptosis. | 1997 | Transplantation | pmid:9371682 |
| Fabrega AJ et al. | Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. | 1993 | Transplantation | pmid:7506458 |
| Sankary HN et al. | FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. | 1998 | Transplantation | pmid:9798690 |
| Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
| Sofi AA et al. | Bullous pemphigoid associated with acute renal allograft rejection. | 2010 | Transplantation | pmid:20145531 |
| Butani L et al. | Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. | 2003 | Transplantation | pmid:12883183 |
| Ito A et al. | Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. | 1997 | Transplantation | pmid:9311715 |
| Marcén R et al. | Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. | 2006 | Transplantation | pmid:16570003 |
| Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
| Sood P et al. | Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. | 2012 | Transplantation | pmid:23018881 |
| Vennarecci G et al. | Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. | 2001 | Transplantation | pmid:11455248 |
| Schulman SL et al. | Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. | 1998 | Transplantation | pmid:9625026 |
| Shimada T et al. | Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. | 2002 | Transplantation | pmid:12451243 |
| Herlenius G et al. | Chronic kidney disease--a common and serious complication after intestinal transplantation. | 2008 | Transplantation | pmid:18622286 |
| Ceulemans LJ et al. | Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. | 2015 | Transplantation | pmid:25695790 |
| Glicklich D et al. | Chronic renal allograft rejection: no response to mycophenolate mofetil. | 1998 | Transplantation | pmid:9721811 |
| Calandra S | Sinus arrest during tacrolimus treatment: was the QT interval prolonged? | 1998 | Transplantation | pmid:9721813 |
| Eckhoff DE et al. | The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. | 2000 | Transplantation | pmid:10830224 |
| Ji E et al. | Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. | 2012 | Transplantation | pmid:22992768 |
| Fukushima D et al. | Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. | 2015 | Transplantation | pmid:24846306 |
| Klein A et al. | Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. | 2009 | Transplantation | pmid:19300186 |
| Beckebaum S et al. | Predictive factors of outcome in patients transplanted for hepatitis B. | 2009 | Transplantation | pmid:19300191 |
| Mazariegos GV et al. | Weaning of immunosuppression in liver transplant recipients. | 1997 | Transplantation | pmid:9020325 |
| Marks WH et al. | Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. | 1997 | Transplantation | pmid:9020333 |
| Pascual J et al. | Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. | 2011 | Transplantation | pmid:21336083 |
| Egli A et al. | Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. | 2013 | Transplantation | pmid:23274966 |
| Wennberg L et al. | The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. | 2005 | Transplantation | pmid:15665763 |
| Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
| Thai NL et al. | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. | 2006 | Transplantation | pmid:17198247 |
| Krähenbühl S et al. | Serious interaction between mibefradil and tacrolimus. | 1998 | Transplantation | pmid:9808502 |
| Peduto G et al. | Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. | 2000 | Transplantation | pmid:10919579 |
| Aisa Y et al. | Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. | 2005 | Transplantation | pmid:16278584 |
| Yoshimura N et al. | A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). | 1996 | Transplantation | pmid:8633388 |
| Wang HD et al. | Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. | 2018 | Transplantation | pmid:29298238 |
| Dharancy S et al. | Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. | 2007 | Transplantation | pmid:17460561 |